Loading
Intuitive Surgical Inc Stock: price and insider trades · United States
Intuitive Surgical Inc: what insiders have been doing
This page follows insider dealings at Intuitive Surgical Inc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Sunnyvale, United States. The group dates from 1995. Over the twelve months to 18 October 2026, 107 filings were filed, from 26 insiders.
All open-market trades in the period are sales: 35 sales worth €6.6M, by 6 insiders, with no purchase on record. No amount is published for 5 filings, which the totals therefore leave out. One trade stands out by size: a sale of €3.5M from Guthart Gary S, disclosed on 12 August 2026, or 0.0028% of market capitalisation.
For context, the typical company on the same exchange (median of 5,810 companies) published 19 filings over the same period, against 107 filings here. Since 2016, the database holds no purchases and 69 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 10.06 bn USD and net income at 2.86 bn USD.
Typically, a trade is published a median of 1 day after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
415
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€14M
69 ops. · all time
Who traded when
BuySaleMark Brosius31 sales
Amy L. Ladd6 sales
Fredrik Widman3 sales
Gary Loeb2 sales
Curet Myriam1 sale
Gary S. Guthart1 sale
Analyst consensus: bullish or bearish?
Analysts rate Intuitive Surgical Inc Buy (bullish), based on 30 analysts. Average price target: US$478.10.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 7,735 of 24,148 companies
60.5
score / 100
Value33
Quality89
FCF yld1.7%
Earn yld1.9%
EV/EBITDA41.0x
ROE17%
Gross mgn66%
Net mgn28%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2021FY ended December 2021 · cache
US$420.24
Analyst consensus
30 analystsBuy
US$324.00Target US$478.10(+14%)US$685.00
Income statement
RevenueUS$10.1B
Gross profitUS$6.6B66% margin
EBITDAUS$3.6B36% margin
Net incomeUS$2.9B28.4% margin
Valuation
PER (trailing)48.2x
PER (forward)34.7x
P/Book8.2x
Beta1.46
Balance sheet & cash
Market capUS$148.5B
Total debtUS$87M
Free Cash FlowUS$2.5B
Profitability & ownership
ROE17.4%
ROA10.5%
% insiders0.5%
% institutions89.5%
Last declaration on 13 October 2026
Declarations415 total
2,140 shares0Common StockSEC:0001274559-26-000005:0
1,062 shares@ US$423.960.0003% mcap100.0% of flowCommon StockSEC:0001274559-26-000005:1
546 shares@ US$79.63780.0000% mcap1.5% of flowCommon StockSEC:0001897970-26-000008:0
546 shares@ US$374.440.0001% mcap6.9% of flowCommon StockSEC:0001897970-26-000008:1
543 shares@ US$109.48560.0000% mcap2.0% of flowCommon StockSEC:0001897970-26-000008:2
543 shares@ US$374.440.0001% mcap6.9% of flowCommon StockSEC:0001897970-26-000008:3
2,178 shares@ US$377.940.050% mcap100.0% of flowCommonSEC144:0001950047-26-009515
23 shares@ US$347.660.0000% mcap0.2% of flowCommon StockSEC:0002010300-26-000033:0
25 shares@ US$365.790.0000% mcap0.3% of flowCommon StockSEC:0002010300-26-000033:1
46 shares@ US$361.230.0000% mcap0.5% of flowCommon StockSEC:0002010300-26-000031:0
23 shares@ US$350.200.0000% mcap0.3% of flowCommon StockSEC:0002010300-26-000031:1
694 shares@ US$366.700.0002% mcap100.0% of flowCommonSEC144:0001950047-26-009210
77 shares@ US$396.370.0000% mcap1.0% of flowCommon StockSEC:0002010300-26-000029:0
77 shares@ US$375.570.0000% mcap0.9% of flowCommon StockSEC:0002010300-26-000029:1
77 shares@ US$394.000.0000% mcap1.0% of flowCommon StockSEC:0002010300-26-000027:1
77 shares@ US$390.670.0000% mcap0.9% of flowCommon StockSEC:0002010300-26-000027:0
77 shares@ US$394.260.0000% mcap1.0% of flowCommon StockSEC:0002010300-26-000027:2
10,000 shares@ US$400.000.0028% mcap9.0% of flowCommon StockSEC:0001280628-26-000014:0
20,095 shares@ US$393.380.48% mcap100.0% of flowCommonSEC144:0001950047-26-007955
400 shares@ US$379.000.0001% mcap8.6% of flowCommon StockSEC:0001781750-26-000006:0
72 shares@ US$393.100.0000% mcap1.6% of flowCommon StockSEC:0001781750-26-000006:1
472 shares@ US$378.810.011% mcap100.0% of flowCommonSEC144:0001950047-26-007884
25 of 415 declarations
About Intuitive Surgical Inc
Intuitive Surgical Inc. is a flagship U.S. medtech company listed on the NASDAQ in the United States. Founded in 1995 and headquartered in Sunnyvale, California, the company is widely recognized as the pioneer of robotic-assisted minimally invasive surgery. From an investor’s perspective, ISRG is best understood as a platform business: it sells robotic systems, instruments and accessories, and services, creating a meaningful recurring-revenue profile and a sticky installed base in hospitals and ambulatory settings. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1035267/000103526725000099/a2024_intuitiveannualrepor.pdf?utm_source=openai))
The company’s core franchise is the da Vinci family of surgical robotic systems, complemented by the Ion endoluminal system for lung biopsy and other endoluminal applications. Intuitive serves a broad range of procedures, including urology, gynecology, general surgery, thoracic surgery, colorectal surgery, and selected ENT applications, depending on regulatory approvals in each market. A major strategic step has been the rollout of da Vinci 5, the company’s newest platform generation, which adds software capabilities and real-time surgical insights aimed at improving workflow efficiency and system performance. ([intuitive.com](https://www.intuitive.com/en-us?utm_source=openai))
Read moreShow less
Competitive positioning remains one of Intuitive’s key strengths. The company is the global leader in surgical robotics, supported by strong brand equity, a large installed base, broad surgeon familiarity, and an ecosystem of training, clinical support, and service that is difficult for competitors to replicate quickly. That leadership has continued to translate into healthy procedure growth in 2025, with management updates highlighting rising worldwide usage across da Vinci and Ion, as well as increasing adoption of da Vinci 5. ([isrg.intuitive.com](https://isrg.intuitive.com/news-releases/news-release-details/intuitive-announces-preliminary-fourth-quarter-and-full-year-5?utm_source=openai))
Geographically, Intuitive is a U.S.-based company with a global commercial footprint across North America, Europe, and other developed international markets. Recent milestones have reinforced its innovation pipeline: the FDA expanded da Vinci SP indications in 2025, Intuitive introduced new real-time software features for da Vinci 5, enhanced AI and imaging integration in Ion, and received CE Mark approval for da Vinci 5 in Europe. For equity investors, the combination of technology leadership, recurring revenue, and secular adoption of minimally invasive surgery underpins the long-term thesis. ([isrg.intuitive.com](https://isrg.intuitive.com/news-releases/news-release-details/intuitive-announces-fda-clearance-da-vinci-single-port-transanal?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
